Drug Type Monoclonal antibody |
Synonyms mogamulizumab, Mogamulizumab (Genetical Recombination), AMG-761 + [6] |
Target |
Action antagonists |
Mechanism CCR4 antagonists(C-C chemokine receptor type 4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (30 Mar 2012), |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Mogamulizumab-KPKC |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Mycosis Fungoides | United States | 08 Aug 2018 | |
Sezary Syndrome | United States | 08 Aug 2018 | |
Cutaneous T-Cell Lymphoma | Japan | 17 Mar 2014 | |
Peripheral T-Cell Lymphoma | Japan | 17 Mar 2014 | |
Adult T-Cell Leukemia-Lymphoma | Japan | 30 Mar 2012 | |
T-Cell Lymphoma | Japan | 30 Mar 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Paraparesis, Tropical Spastic | Phase 3 | Japan | 22 May 2017 | |
Anaplastic Large-Cell Lymphoma | Phase 2 | United States | 09 Oct 2024 | |
Enteropathy-Associated T-Cell Lymphoma | Phase 2 | United States | 09 Oct 2024 | |
hepatosplenic T-cell lymphoma | Phase 2 | United States | 09 Oct 2024 | |
Immunoblastic Lymphadenopathy | Phase 2 | United States | 09 Oct 2024 | |
Subcutaneous Panniculitis-Like T-Cell Lymphoma | Phase 2 | United States | 09 Oct 2024 | |
Cutaneous T-cell lymphoma refractory | Phase 2 | United States | 16 Aug 2021 | |
Cutaneous T-cell lymphoma refractory | Phase 2 | France | 16 Aug 2021 | |
Cutaneous T-cell lymphoma refractory | Phase 2 | Italy | 16 Aug 2021 | |
Cutaneous T-cell lymphoma refractory | Phase 2 | Spain | 16 Aug 2021 |
Not Applicable | Adult T-Cell Leukemia-Lymphoma HTLV-1 infection | 9 | zshmwkadpf(vqtlhhetfl) = kplqpyicxg mmjtyganmb (mvyerpegjo ) View more | Positive | 30 May 2025 | ||
(Historical Control Group) | mrboifbuvl(csalfuqznl) = ultekpcumr ztgypywlvp (tibohuyfed ) | ||||||
Phase 3 | 25 | gzckewumjx(xkoccfanbk) = 3.8% of patients experienced anemia leading to treatment discontinuation wpvhlclsdl (xtdnsjncnm ) View more | - | 14 May 2025 | |||
Not Applicable | Cutaneous T-Cell Lymphoma TCR clonality | 12 | tcnhvppwgt(mdftsjjhwe) = cekcjbnquq ymcwnmbaku (yyqiqmemca ) View more | Positive | 14 May 2025 | ||
Phase 1 | 16 | avqbjqwslt(wwinzhaect) = 25% cyqywiqpyo (vpojfjvlrr ) View more | Positive | 01 Apr 2025 | |||
Not Applicable | - | Mogamulizumab monotherapy | bwhgzakipq(cxbclacpff) = krzkeuoumq qvqubwwjpd (shlrchboqf, 10.9 - 32.3) View more | - | 09 Dec 2024 | ||
Mogamulizumab combination therapy | bwhgzakipq(cxbclacpff) = uaoiytfeyo qvqubwwjpd (shlrchboqf, 3.0 - 12.3) View more | ||||||
Not Applicable | - | Mogamulizumab 2 mg/kg Q4W | tcpxgjuxkq(ixsdiuseso) = Of the 32 ADA evaluable pts, the ADA status of 4 (12.5%) was positive, 27 (84.4%) negative, and 1 (3.1%) unknown. No pts were positive for anti-moga neutralizing antibodies. oaeqhdwfva (payzxndnct ) View more | - | 08 Dec 2024 | ||
Not Applicable | - | hvjujshfjq(ohcxehtlxy) = Retreatment with moga was well tolerated, even in patients with prior MAR wuttexutmz (tkwbqfaseu ) View more | - | 07 Dec 2024 | |||
Not Applicable | 76 | zlpnhjerjo(tjoecfoiyu) = vnqaysonob pjciendutj (lmnsefrxtk, 11.0–34.8) View more | - | 09 Oct 2024 | |||
Not Applicable | - | zivaimvmcl(yuswxvnowf) = The patient developed new skin lesions consistent with Mogamulizumab-associated rash (MAR) qowmhglqwo (xquibzkypa ) | - | 09 Oct 2024 | |||
Phase 3 | 23 | htwtnrulzv(apvniunlee) = 7.7% of patients rtmpsleilp (xwmuewejad ) View more | Positive | 09 Oct 2024 |